Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ifferences,

if any, in the rates of valvulopathy (as defined by the Food and Drug

Administration, or FDA) in patients treated with lorcaserin and in the

control group did not meet the ESMB's predetermined stopping criteria.

o Announced the initiation of a Phase 1 clinical trial of a second

generation oral niacin receptor agonist intended for the treatment of

atherosclerosis in partnership with Merck & Co., Inc.

o Entered into strategic agreements with Siegfried Ltd primarily related

to the manufacturing of lorcaserin for Arena's planned New Drug

Application submission to the FDA and for commercialization of

lorcaserin after regulatory marketing approval. The agreements include

the purchase of certain drug product manufacturing and packaging

facility assets, including fixtures, equipment, other personal property

and real estate assets, located in Zofingen, Switzerland.

o Reported positive Phase 1a clinical trial results of APD791, Arena's

oral, internally discovered drug candidate intended for the treatment of

arterial thrombosis, and initiated a Phase 1b clinical trial to further

evaluate this drug candidate.

o Announced that initial clinical trial results for APD668, an oral drug

candidate discovered by Arena and being investigated for the treatment

of type 2 diabetes in partnership with Ortho-McNeil Pharmaceutical,

Inc., suggest that the Glucose-Dependent Insulinotropic Receptor, or

GDIR, improves glucose control in patients with type 2 diabetes. Based

on the data from those studies, Ortho-McNeil put APD668 on hold and

advanced a potentially more potent Arena-discovered GDIR agonist into

preclinical development.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the first quarter 2008 financial results and to provide a corporat
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2
Other Biology Technology:Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 2Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 4Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 2Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 3Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 4Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 5Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 6Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 7Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 8Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 9NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 2NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 3